Skip to main content

Table 2 Diseases in which tumor necrosis factor (TNF) blockade is therapeutic

From: Multiple roles for tumor necrosis factor-α and lymphotoxin α/β in immunity and autoimmunity

Disease Intervention Result Mechanism Reference
1a. Rheumatoid arthritis Anti-TNF, soluble TNFR 65% of patients have a dramatic decrease in disease activity Blockade of TNF-induced inflammatory response (? decreased macrophage activation) [16]
1b. Rheumatoid arthritis Anti-TNF, soluble TNFR Up to 15% of patients develop α-dsDNA antibodies. 0.2% develop mild SLE ? T-cell activation [16]
1c. Rheumatoid arthritis Anti-TNF, soluble TNFR A few patients develop CNS findings suggestive of MS ? T-cell activation [17]
2. Crohn's disease Anti-TNF, soluble TNFR Dramatic decrease in disease activity in up to 80% of patients ? Decreased monocyte/macrophage activation [18]
3. Psoriasis Anti-TNF Dramatic clearing of skin lesions, decrease in associated arthritis Blockade of TNF-induced inflammation [19]
  1. CNS, central nervous system; MS, multiple sclerosis; SLE, systemic lupus erythematosus; TNFR, TNF receptor.